miR-33a levels in hepatic and serum after chronic HBV-induced fibrosis

详细信息    查看全文

• 作者：Chuan-Feng Huang ; Cheng-Chao Sun ; Fang Zhao ; Ya-Dong Zhang…
• 关键词：Liver fibrosis ; HBV ; Hepatic stellate cells ; microRNA 33a ; TGF ; β1
• 刊名：Journal of Gastroenterology
• 出版年：2015
• 出版时间：April 2015
• 年：2015
• 卷：50
• 期：4
• 页码：480-490
• 全文大小：1,185 KB
• 参考文献：1. Guha, IN, Myers, RP, Patel, K (2011) Biomarkers of liver fibrosis: what lies beneath the receiver operating characteristic curve?. Hepatology 54: pp. 1454-1462 CrossRef
  2. Fallowfield, JA (2011) Therapeutic targets in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 300: pp. G709-G715 CrossRef
  3. Friedman, SL (2010) Evolving challenges in hepatic fibrosis. Nat Rev Gastroenterol Hepatol 7: pp. 425-436 CrossRef
  4. Zhang, L, Wang, G, Hou, W (2010) Contemporary clinical research of traditional Chinese medicines for chronic hepatitis B in China: an analytical review. Hepatology 51: pp. 690-698 CrossRef
  5. Ji, F, Yang, B, Peng, X (2011) Circulating microRNAs in hepatitis B virus-infected patients. J Viral Hepat 18: pp. e242-e251 CrossRef
  6. Zhou, YH, Wu, C, Zhuang, H (2009) Vaccination against hepatitis B: the Chinese experience. Chin Med J (Engl) 122: pp. 98-102
  7. Iizuka, M, Ogawa, T, Enomoto, M (2012) Induction of microRNA-214-5p in human and rodent liver fibrosis. Fibrogenesis Tissue Repair 5: pp. 12 CrossRef
  8. Bartel, DP (2009) MicroRNAs: target recognition and regulatory functions. Cell 136: pp. 215-233 CrossRef
  9. Shukla, GC, Singh, J, Barik, S (2011) MicroRNAs: processing maturation, target recognition and regulatory functions. Mol Cell Pharmacol 3: pp. 83-92
  10. Auyeung, VC, Ulitsky, I, McGeary, SE (2013) Beyond secondary structure: primary-sequence determinants license pri-miRNA hairpins for processing. Cell 152: pp. 844-858 CrossRef
  11. Stefani, G, Slack, FJ (2008) Small non-coding RNAs in animal development. Nat Rev Mol Cell Biol 9: pp. 219-230 CrossRef
  12. Santa, F, Iosue, I, Del Rio, A (2013) microRNA biogenesis pathway as a therapeutic target for human disease and cancer. Curr Pharm Des 19: pp. 745-764 CrossRef
  13. Bavan, L, Midwood, K, Nanchahal, J (2011) MicroRNA epigenetics: a new avenue for wound healing research. BioDrugs 25: pp. 27-41 CrossRef
  14. Zhao, L, Chen, X, Cao, Y (2011) New role of microRNA: carcinogenesis and clinical application in cancer. Acta Biochim Biophys Sin (Shanghai) 43: pp. 831-839 CrossRef
  15. Iorio, MV, Croce, CM (2012) microRNA involvement in human cancer. Carcinogenesis 33: pp. 1126-1133 CrossRef
  16. Stather PW, Sylvius N, Wild JB, et al. Differential MicroRNA expression profiles in peripheral arterial disease Circ Cardiovasc Genet 2013.
  17. Ciccacci, C, Di Fusco, D, Cacciotti, L (2013) MicroRNA genetic variations: association with type 2 diabetes. Acta Diabetol 50: pp. 867-872 CrossRef
  18. Goedeke, L, Vales-Lara, FM, Fenstermaker, M (2013) A regulatory role for microRNA 33* in controlling lipid metabolism gene expression. Mol Cell Biol 33: pp. 2339-2352 CrossRef
  19. Rayner, KJ, Esau, CC, Hussain, FN (2011) Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature 478: pp. 404-407 CrossRef
  20. Davalos, A, Goedeke, L, Smibert, P (2011) miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling. Proc Natl Acad Sci USA
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Gastroenterology
  Oncology
  Surgical Oncology
  Hepatology
  Internal Medicine
  Colorectal Surgery
  
• 出版者：Springer Japan
• ISSN：1435-5922

文摘

Background Chronic hepatitis B virus (HBV) infection, which can lead to hepatic disease, has become a critical national healthcare problem, and many people die each year as a result of HBV infection and its complications. Although microRNA-33a (miR-33a) is a novel modulator of lipid and cholesterol metabolism, the role of miR-33a in the hepatic fibrogenesis is still unknown. Here, we aimed to explore the roles and mechanisms of miR-33a in liver fibrosis. Methods miR-33a expression in whole liver and serum samples was measured from chronic hepatitis B (CHB) patients by quantitative real-time PCR?(qRT-PCR). In addition, different murine hepatic fibrosis models were produced to consolidate the results in human tissue. Human and murine primary liver fibrosis-associated cells were isolated and treated with transforming growth factor-β1 (TGF-β1). Results miR-33a expression levels in liver tissue significantly increased with a fibrosis progression manner in the human liver. Furthermore, serum miR-33a levels associated positively with progressing process of hepatic fibrosis. miR-33a was in particular increased in hepatic stellate cells (HSC) than other liver fibrosis-associated cells. Stimulation of HSCs with TGF-β1 leads to a critical increase of miR-33a. Increasing miR-33a levels increased (whereas inhibiting miR-33a weakened) the activation role of TGF-β1 in LX-2 cells, which might be a potential mechanism through moderating Smad7 expression. Conclusions miR-33a may be a novel marker for HSC activation and hepatic fibrosis progress, suggesting a new therapeutic target in liver fibrosis.